Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Gynecologic Oncology
|
January 26, 2022
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
Alicia Leon-Castillo, Nanda Horeweg, Elke E M Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 23, 2013
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998)
R B Keus, R A Nout, J-Y Blay, et al.
Gynecologic Oncology
|
August 7, 2018
Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
B G Wortman, T Bosse, R A Nout, et al.
Oncoimmunology
|
March 28, 2017
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
H van Meir, R A Nout, M J P Welters, et al.
Lancet (London, England)
|
March 9, 2010
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
R A Nout, V T H B M Smit, H Putter, et al.
Breast (Edinburgh, Scotland)
|
August 7, 2025
The association between breast fibrosis, cosmetic outcomes, and long-term health-related quality of life after breast-conserving therapy: a multicenter cross-sectional observational cohort study
M C A W Notenboom, T M A L Klem, C M E Contant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2017
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S M de Boer, B G Wortman, T Bosse, et al.
Gynecologic Oncology
|
August 17, 2020
Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study
J Knoth, R Pötter, I M Jürgenliemk-Schulz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 11, 2025
Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy
A Corbeau, E Astreinidou, S C Kuipers, et al.
British Journal of Cancer
|
October 26, 2018
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
B G Wortman, C L Creutzberg, H Putter, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Gynecologic Oncology
|
January 26, 2022
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
Alicia Leon-Castillo, Nanda Horeweg, Elke E M Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 23, 2013
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998)
R B Keus, R A Nout, J-Y Blay, et al.
Gynecologic Oncology
|
August 7, 2018
Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
B G Wortman, T Bosse, R A Nout, et al.
Oncoimmunology
|
March 28, 2017
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
H van Meir, R A Nout, M J P Welters, et al.
Lancet (London, England)
|
March 9, 2010
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
R A Nout, V T H B M Smit, H Putter, et al.
Breast (Edinburgh, Scotland)
|
August 7, 2025
The association between breast fibrosis, cosmetic outcomes, and long-term health-related quality of life after breast-conserving therapy: a multicenter cross-sectional observational cohort study
M C A W Notenboom, T M A L Klem, C M E Contant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2017
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S M de Boer, B G Wortman, T Bosse, et al.
Gynecologic Oncology
|
August 17, 2020
Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study
J Knoth, R Pötter, I M Jürgenliemk-Schulz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 11, 2025
Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy
A Corbeau, E Astreinidou, S C Kuipers, et al.
British Journal of Cancer
|
October 26, 2018
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
B G Wortman, C L Creutzberg, H Putter, et al.
Page
of 4